Differentiated thyroid cancer, lung metastasis, I-131.
Main Article Content
Abstract
Objective: Evaluate the treatment results of differentiated thyroid cancer (DTC) with lung metastasis using I-131 at Nghe An Oncology Hospital. Subjects and methods: A retrospective and prospective descriptive study of 45 DTC patients with lung metastasis diagnosed by whole-body scintigraphy and to evaluate the treatment results with I-131 at the Department of Nuclear Medicine, Nghe An Oncology Hospital from January 2018 to May 2024. Results: DTC patients with lung metastasis had an average age of 47.26 ± 15.75 years old, with a male-to-female ratio of 1/2.5. The pathological type was mainly papillary with a rate of 93.3%. The average thyroglobulin level at the time of stopping the drug was 112.32 ± 154.7 ng/ml. The lesions on whole-body I-131 scan were mainly diffuse hyperactivity with a rate of 77,8%. Patients were treated multiple times with I-131, an average of 3.75 times and had a total cumulative treatment dose of 540 ± 193,73 mCi (150-970). The rate of complete response to I-131 accounted for 17.8%. The rates of incomplete and indeterminate responses were 64.44% and 17.8%, respectively. Age and thyroglobulin stimulation were two valuable factors in predicting the response to I-131 treatment in DTC patients with lung metastases. Conclusion: DTC patients with lung metastasis treated with I-131 at Nghe An Oncology Hospital had a complete response rate of 17.8%, incomplete and undetermined response rates of 64.44% and 17.8%, respectively.
Keywords
Differentiated thyroid cancer, lung metastasis, I-131.
Article Details
References
2. Bray F., Laversanne M., Sung H., et al. (2024). Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 74(3), 229–263.
3. Đỗ Thị Thanh Toàn, Nguyễn Bích Nguyệt, and Trần Thị Thanh Hương (2021). Tổng quan xu hướng mắc mới bệnh ung thư tuyến giáp trên thế giới và Việt Nam, giai đoạn 2009-2019. TCNCYH, 144(8), 58–67.
4. Links T.P., van Tol K.M., Jager P.L., et al. (2005). Life expectancy in differentiated thyroid cancer: a novel approach to survival analysis. Endocr Relat Cancer, 12(2), 273–280.
5. Kim T.Y., Kim W.G., Kim W.B., et al. (2014). Current Status and Future Perspectives in Differentiated Thyroid Cancer. Endocrinol Metab (Seoul), 29(3), 217–225.
6. Mai Trọng Khoa (2011). Nghiên cứu đặc điểm ung thư biểu mô tuyến giáp thể biệt hóa di căn phổi và kết quả điều trị bằng I-131. Y học thực hành, 762(4), 148–152.
7. Wang R., Zhang Y., Tan J., et al. (2017). Analysis of radioiodine therapy and prognostic factors of differentiated thyroid cancer patients with pulmonary metastasis. Medicine (Baltimore), 96(19), e6809.
8. Haugen B.R., Alexander E.K., Bible K.C., et al. (2016). 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid, 26(1), 1–133.
9. Thyroid.pdf. , accessed: 09/17/2024.
10. Song H.-J., Qiu Z.-L., Shen C.-T., et al. (2015). Pulmonary metastases in differentiated thyroid cancer: efficacy of radioiodine therapy and prognostic factors. Eur J Endocrinol, 173(3), 399–408.
11. Chang G.J. AJCC Cancer Staging 8th Edition. .
12. Kim H., Kim H.I., Kim S.W., et al. (2018). Prognosis of Differentiated Thyroid Carcinoma with Initial Distant Metastasis: A Multicenter Study in Korea. Endocrinol Metab, 33(2), 287–295.
13. Samaan N.A., Schultz P.N., Haynie T.P., et al. (1985). Pulmonary Metastasis of Differentiated Thyroid Carcinoma: Treatment Results in 101 Patients*. The Journal of Clinical Endocrinology & Metabolism, 60(2), 376–380.
14. Durante C., Haddy N., Baudin E., et al. (2006). Long-Term Outcome of 444 Patients with Distant Metastases from Papillary and Follicular Thyroid Carcinoma: Benefits and Limits of Radioiodine Therapy. The Journal of Clinical Endocrinology & Metabolism, 91(8), 2892–2899.
15. Cho S.W., Choi H.S., Yeom G.J., et al. (2014). Long-Term Prognosis of Differentiated Thyroid Cancer with Lung Metastasis in Korea and Its Prognostic Factors. Thyroid®, 24(2), 277–286.
16. Ronga G., Filesi M., Montesano T., et al. (2004). Lung metastases from differentiated thyroid carcinoma. A 40 years’ experience. Q J Nucl Med Mol Imaging, 48(1), 12–19.
17. Ilgan S., Karacalioglu A.O., Pabuscu Y., et al. (2004). Iodine-131 treatment and high-resolution CT: results in patients with lung metastases from differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging, 31(6), 825–830.
18. Dinauer C.A., Breuer C., and Rivkees S.A. (2008). Differentiated thyroid cancer in children: diagnosis and management. Current Opinion in Oncology, 20(1), 59.
19. Hirsch D., Levy S., Tsvetov G., et al. (2017). Long-term outcomes and prognostic factors in patients with differentiated thyroid cancer and distant metastases. Endocr Pract, 23(10), 1193–1200.
20. Livhits M.J., Pasternak J.D., Xiong M., et al. (2016). Pre-ablation thyroglobulin and thyroglobulin to thyroidstimulating hormone ratio may be associated with pulmonary metastases in children with differentiated thyroid cancer. Endocr Pract, 22(11), 1259–1266.
21. Machens A., Holzhausen H.-J., and Dralle H. (2005). The prognostic value of primary tumor size in papillary and follicular thyroid carcinoma. Cancer, 103(11), 2269–2273.
22. Chesover A.D., Vali R., Hemmati S.H., et al. (2021). Lung Metastasis in Children with Differentiated Thyroid Cancer: Factors Associated with Diagnosis and Outcomes of Therapy. Thyroid, 31(1), 50–60.
23. Follicular Thyroid Cancer. , accessed: 06/23/2024.
24. Bal C.S., Kumar A., Chandra P., et al. (2004). Is chest x-ray or high-resolution computed tomography scan of the chest sufficient investigation to detect pulmonary metastasis in pediatric differentiated thyroid cancer?. Thyroid, 14(3), 217–225.
25. Jang S., Chung J.-K., Kang K.W., et al. (2009). Assessment of pulmonary uptake in post-therapy I-131 whole body scan in well differentiated thyroid cancer patients. Journal of Nuclear Medicine, 50(supplement 2), 389–389.
26. Shammas A., Degirmenci B., Mountz J.M., et al. (2007). 18F-FDG PET/CT in Patients with Suspected Recurrent or Metastatic Well-Differentiated Thyroid Cancer. Journal of Nuclear Medicine, 48(2), 221–226.
27. Kalshetty A. and Basu S. (2023). Assessment of Pulmonary Metastasis in Differentiated Thyroid Carcinoma: Value of HRCT Correlation with Functional Imaging. World J Nucl Med, 87–99.
28. Heemstra K.A., Liu Y.Y., Stokkel M., et al. (2007). Serum thyroglobulin concentrations predict disease-free remission and death in differentiated thyroid carcinoma. Clinical Endocrinology, 66(1), 58–64.
29. Nguyễn Thành Công, Lê Thanh Thượng, and Võ Khắc Nam (2023). Hiệu quả điều trị ung thư tuyến giáp thể biệt hóa sau phẫu thuật, di căn phổi bằng I-131. TC YDTH 175, (30), 8.
30. Luster M., Clarke S.E., Dietlein M., et al. (2008). Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging, 35(10), 1941–1959.